1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsInnovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) is sponsored by National Institutes of Health. Supports initial translational efforts in neurotherapeutic agent characterization and efficacy studies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) | Research Funding National Institutes of Health Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) This Notice of Funding Opportunity (NOFO) provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission.
Therapeutic agents include small molecules or biologics. This NOFO is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE). This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).
PAR-25-059 , R61 / R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II PAR-25-060 , R61 / R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II Application Due Dates: Feb 18, 2025; June 18, 2025; Oct 20, 2025; Feb 18, 2026; June 18, 2026; Oct 20, 2026; Feb 18, 2027; June 18, 2027; Oct 20, 2027 PAR-25-225 Expiration Date October 21, 2027 Direct Costs cannot exceed $499,000 in any one year and cumulative direct costs for the three year project cannot exceed $750,000.
Medical - Clinical Science
According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments, For-profit organizations, Small businesses, Public and State controlled institutions of higher education, Private institutions of higher education, Independent school d…. Confirm the full requirements in the official notice before applying.
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) is funded by National Institutes of Health. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Merck Stimulating Innovative Research Grant Program 2026 includes a dedicated grant topic for artificial intelligence in cell culture media and process development, offering up to EUR 150,000 per year for up to 3 years. The program accelerates innovation through collaborative research, early engagement with industry experts, and translation of novel ideas into practical solutions. In 2026, priority areas also include in-vitro models for neuroinflammatory diseases (EUR 250,000/year for 2 years) and innovative approaches to contaminated materials remediation (EUR 150,000/year for 2 years). The two-stage application process begins with non-confidential submissions, followed by deep-dive workshops where finalists collaborate with Merck scientists and managers to jointly optimize proposals. The AI-specific grant focuses on applying machine learning and AI to optimize cell culture media formulation, bioprocess parameter optimization, and manufacturing quality control.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs (NIH) is sponsored by National Institutes of Health (NIH). These programs provide non-dilutive funding to U.S. small businesses for research and development (R&D) of innovative technologies that align with NIH's mission to improve health. This includes health IT solutions with strong commercialization potential.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article